Comparative Pharmacology
Head-to-head clinical analysis: ATORVALIQ versus FLUVASTATIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVALIQ versus FLUVASTATIN SODIUM.
ATORVALIQ vs FLUVASTATIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATORVALIQ is a combination of atorvastatin and amlodipine. Atorvastatin is an HMG-CoA reductase inhibitor that decreases cholesterol synthesis in the liver. Amlodipine is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased intracellular cholesterol levels and upregulation of LDL receptors.
10-80 mg orally once daily. Starting dose 10-20 mg. Max dose 80 mg.
20 to 80 mg orally once daily in the evening; immediate-release: 20-40 mg once daily; extended-release: 80 mg once daily.
None Documented
None Documented
The terminal elimination half-life of atorvastatin is approximately 14 hours; however, its active metabolites have a half-life of 20-30 hours, allowing for once-daily dosing.
The terminal elimination half-life is 2.3 hours (range 1.4–3.1 hours). Due to its short half-life, it is dosed once daily for sustained HMG-CoA reductase inhibition; however, pharmacodynamic effects (LDL reduction) persist beyond plasma clearance.
Atorvastatin is primarily eliminated via biliary/fecal excretion (approximately 70% as metabolites), with renal excretion accounting for less than 2% of the administered dose.
Fluvastatin sodium is primarily eliminated via biliary/fecal excretion (approximately 90%), with renal excretion accounting for less than 6% of the administered dose.
Category C
Category D/X
Statin
Statin